AstraZeneca leukemia drug Calquence gets USFDA okay Medical Dialogues Bureau24 Nov 2019 4:30 AM GMTNew Delhi: AstraZeneca said late on Thursday that the U.S. Food and Drug Administration (FDA) had given its go-ahead for the company's Calquence drug...
Johnson and Johnson found negligent in landmark vaginal mesh lawsuit in Australia Medical Dialogues Bureau23 Nov 2019 3:48 AM GMTAustralia's Federal Court found that Johnson and Johnson (JnJ) subsidiary Ethicon had sold the devices (pelvic mesh implants) without warning women...
JnJ enters series of new collaborations with Government, NGOs for ending TB in India by 2025 Farhat Nasim31 Oct 2019 7:09 AM GMTHyderabad: Johnson & Johnson(JnJ) recently announced the expansion of its tuberculosis (TB) program in India in advance of the 50th Union World...
New tests shows NO sign of asbestos in recalled JnJ baby powder Medical Dialogues Bureau30 Oct 2019 7:48 AM GMTBut Johnson & Johnson (JnJ) said in a statement that dozens of tests by two outside firms did not detect any asbestos in JnJ's baby powder.New...
Johnson and Johnson hit with whooping USD 8 billion verdict over antipsychotic drug Risperda Medical Dialogues Bureau9 Oct 2019 10:54 AM GMTJohnson and Johnson said the award was "grossly disproportionate with the initial compensatory award in this case, and the company is confident it...
JnJ pledges USD 500 million investment to eliminate HIV, TB by 2030 Medical Dialogues Bureau7 Oct 2019 4:00 AM GMTNEW BRUNSWICK: Johnson & Johnson (JnJ) recently announced it has committed to ensuring more than $500 million is dedicated to world-class research...
GSK receives USFDA panel backing for OTC nicotine oral spray for smoking de-addiction Farhat Nasim19 Sep 2019 4:00 AM GMTJohnson & Johnson (JnJ), GSK Plc's developmental partner, sell the over-the-counter nicotine oral spray in 45 countries, excluding the United...
Former JnJ executive Marianne De Backer to lead Bayer pharma division Medical Dialogues Bureau4 Sep 2019 4:00 AM GMTMarianne De Backer will take the role of Head of Business Development & Licensing at Bayer's pharmaceuticals division, joining from rival JnJ,...
Novartis, Lonza strengthen biosimilars push with MS, arthritis drug deals Medical Dialogues Bureau3 Sep 2019 4:00 AM GMTNovartis's Sandoz generics unit, among the biggest biosimilars makers, on Tuesday, agreed to license from Poland's Polpharma Biologics a version of...
Oklahoma judge to rule in opioid lawsuit against JnJ Medical Dialogues Bureau24 Aug 2019 3:40 AM GMTLawyers for the state called JnJ an opioid "kingpin" and contended its marketing efforts created a public nuisance in the form of the opioid crisis as...
Allergan, Endo agree to USD 15 million settlement in major opioid case Medical Dialogues Bureau24 Aug 2019 3:30 AM GMTAllergan has tentatively agreed to pay $5 million to resolve claims involving its branded opioids, though the deal does not resolve claims involving...
Oklahoma judge denies motion to end case against drugmaker JnJ Medical Dialogues Bureau9 July 2019 3:30 AM GMTDistrict Judge Thad Balkman denied Johnson & Johnson lawyers' motion asking him to end the case mid-trial and rule in favour of the New Brunswick,...
